NASDAQ: CDTXCidara Therapeutics Inc Stock
$0.51-0.17 (-25%)
Updated Apr 22, 2024
Cidara Therapeutics shares are trading... find out Why CDTX Price Moved with a free WallStreetZen account
Why Price MovedCDTX Price
$0.51
Fair Value Price
$1.07
Market Cap
$46.89M
52 Week Low
$0.50
52 Week High
$1.48
P/E
-1.98x
P/B
-5.71x
P/S
1.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$63.91M
Earnings
-$22.93M
Gross Margin
97.6%
Operating Margin
-35.19%
Profit Margin
-35.9%
Debt to Equity
-9.16
Operating Cash Flow
-$22M
Beta
0.78
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CDTX Overview
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDTX ($0.51) is undervalued by 52.12% relative to our estimate of its Fair Value price of $1.07 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CDTX ($0.51) is significantly undervalued by 52.12% relative to our estimate of its Fair Value price of $1.07 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CDTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDTX due diligence checks available for Premium users.
Be the first to know about important CDTX news, forecast changes, insider trades & much more!
CDTX News
Valuation
CDTX fair value
Fair Value of CDTX stock based on Discounted Cash Flow (DCF)
Price
$0.51
Fair Value
$1.07
Undervalued by
52.49%
CDTX ($0.51) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDTX ($0.51) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CDTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.98x
Industry
16.21x
Market
41x
CDTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.71x
Industry
5.82x
CDTX's financial health
Profit margin
Revenue
$17.6M
Net Income
-$5.6M
Profit Margin
-31.9%
CDTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CDTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$67.0M
Liabilities
$75.2M
Debt to equity
-9.16
CDTX's short-term liabilities ($67.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDTX's short-term assets ($60.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CDTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.7M
Investing
-$178.0k
Financing
$8.0k
CDTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDTX vs Biotech Stocks
Cidara Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.